Home > News > Pharmacogenetics product achieves CE mark for IVD
May 4th, 2006
Pharmacogenetics product achieves CE mark for IVD
Abstract:
Jurilab, a privately-held Finnish biotechnology company, and Nanogen announce that the European CE Mark for IVD (in vitro diagnostic) use has been achieved for the Drugmet pharmacogenetic test.
Nanogen's ten years of pioneering research involving nanotechnology holds the promise of miniaturization and continues to be supported for its potential for diagnostic and biodefence applications.
Source:
laboratorytalk.com
Bookmark:
| Related Links |
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||